Parkinson’s disease is a neurological disorder commonly seen in middle-aged and older adults, clinically characterized by resting tremor, muscle rigidity and bradykinesia and postural abnormalities. The traditional conception is that its pathology is characterized by a reduction of CA9 dopaminergic neurons in the midbrain stromal dense zone and degeneration of the striatal pathway in the stroma, resulting in a reduction of the brain’s poly- versus-barbitone neurotransmitters. Currently, it is believed that PD is a multi-system synaptic protein disorder that forms LEWY bodies and LEWY synapses in the brain, beginning in the medulla oblongata and progressing to the pontine, midbrain, and finally the mesencephalon and the cortex, damaging the limbic system, the visceral-motor system, and the sensory-motor system, and affecting many extra-plasmalemmal systems such as the midbrain dopamine neurons, norepinephrine, 5-HT, and cholinergic neurons, as well as histamine, and neuropeptide systems. and neuropeptide systems. To date, no treatment has been able to cure it, and most effective treatments have been symptomatic. Most patients have mild symptoms in the early stages of the disease, but once a patient is diagnosed, both doctors and patients are faced with the dilemma of whether medication is needed. On the one hand, the patient’s symptoms are mild, and the side effects of medication make the treatment seem to be somewhat more costly than it is worth; on the other hand, Parkinson’s disease is a progressive disease, and failure to take measures leads to fear and aggravates the patient’s psychological burden. Therefore, choosing the appropriate treatment program for early Parkinson’s disease patients, is crucial. Pharmacotherapy 1. Principles of drug therapy: Generally speaking, the treatment goal is divided into three levels: (1) The treatment goal for young, early PD patients is to maintain or restore the ability to work, i.e., the first goal. According to Hoehn-Yahr staging, these patients are mostly in stages I and II; (2) The minimum treatment goal for patients with middle- to late-stage PD is to maintain or restore the ability to take care of themselves, i.e., the second goal. These patients are mostly in stage III according to the Hoehn-Yahr staging; (3) The minimum treatment goal for patients with advanced PD is to alleviate pain and prolong life, i.e., the third goal. According to Hoehn-Yahr staging, these patients are mostly in stage IV and V. (2) Early neuroprotection of PD is the most important goal. 2.Early neuroprotective treatment of PD For newly diagnosed early PD patients, if the symptoms are mild and do not affect the function, they can first take no medication and strengthen the functional exercise. When possible, take some neuroprotective agents. Although, there is no clear neuroprotective drug treatment for PD, but the hypothesis of oxidative stress is still an important theoretical theory of the etiology of PD, antioxidant coenzyme Q10 is a more certain neuroprotectant, studies have shown that the daily use of 320mg-1200mg, may delay the progression of the disease. 3, symptomatic treatment: for patients who have been affected by motor function should be given medication, first of all, should determine whether the patient has cognitive dysfunction, if so, then directly choose levodopa; if there is no cognitive dysfunction, the age of the primary factor should be considered. For patients younger than 65 years old, non-DA drugs can be considered first: (1) amantadine: the drug has improved the main symptoms of most patients, and it is believed that the drug has a certain effect on the prevention of anisocoria, which is suitable for patients in the early stage or all stages of the disease. However, its effect on tremor is slightly worse, and the efficacy is maintained for a shorter period of time, about several months to more than 1 year. (2) Anticholinergic agents: the commonly used drug is Antan, which has a better effect on tremor, and thus is more suitable for early PD patients with tremor as the main cause. The application of this drug should pay attention to the patient’s age and cognitive function. Usually it should be avoided for patients over 65 years old or with cognitive impairment. If, after the above treatment, the desired goal cannot be achieved, or the patient’s condition affects function, the application of the following two types of drugs should be considered: ① Dopamine agonists. ② Compounded levodopa preparations.